Track LeMaitre Vascular, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

LeMaitre Vascular, Inc. LMAT · Stock Open LeMaitre Vascular, Inc. in new tab

95.96 USD
P/E
33.81
EPS
2.72
Yield
0.98%
Safety Score
100
P/B
5.17
ROE
16.55
Beta
0.52
Target Price
118.75 USD
LeMaitre Vascular, Inc. logo

LeMaitre Vascular, Inc.

🧾 Earnings Recap – Q1 2026

LeMaitre Vascular’s shares fell 3.7% post-earnings, reflecting investor disappointment despite solid sales and EPS growth, driven primarily by cautious gross margin guidance and deceleration in unit growth within the distribution business.

  • Sales grew 11% in Q1, driven by an 8% price increase and 2% unit growth, with direct organic sales growing 12.8%; however, the distribution segment saw lower-than-average unit performance, weighing on growth.
  • Gross margin improved 350 basis points year-over-year to 72.7%, but Q2 guidance lowered margins to 72.1% due to new warehouse and tissue processing transfers, signaling near-term margin pressure.
  • Operating expenses rose 6% to $30.6 million despite a 3% overall headcount reduction; operating income increased 41% to $17.8 million with a 27% operating margin.
  • EPS grew 42% to $0.68, boosted by margin expansion and a structurally lower tax rate due to higher foreign-derived intangible income deductions.
  • Full-year revenue guidance affirmed at $280 million for 12% organic growth, but margin guidance only modestly raised, underscoring cautious outlook amid ongoing operational transitions.
📅
Loading chart...
Key Metrics
Earnings dateAug. 4, 2026
P/E33.81
EPS2.72
Book Value17.80
Price to Book5.17
Debt/Equity46.68
% Insiders6.511%
Growth
Revenue Growth0.11%
Earnings Growth0.42%
Estimates
Forward P/E28.24
Forward EPS3.26
Target Mean Price118.75
Dividend
Dividend Yield0.98%
Annual dividends0.90 USD
Ex-Div. DateMay 21, 2026
Payout30.93%
5y avg Yield0.87%

DCF Valuation

Tweak assumptions to recompute fair value for LeMaitre Vascular, Inc. (LMAT)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

LeMaitre Vascular, Inc. Logo LeMaitre Vascular, Inc. Analysis (LMAT)

United States Health Care Official Website Stock

Is LeMaitre Vascular, Inc. a good investment? LeMaitre Vascular, Inc. (LMAT) is currently trading at 95.96 USD. Market analysts have a consensus price target of 118.75 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 33.81. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: LeMaitre Vascular, Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is 3.26.

For income investors, LeMaitre Vascular, Inc. pays a dividend yield of 0.98%. With a payout ratio of 31%, the dividend appears sustainable.

Investor FAQ

Does LeMaitre Vascular, Inc. pay a dividend?

Yes, it pays an annual dividend of 0.90 USD (0.98% yield).

What asset class is LeMaitre Vascular, Inc.?

LeMaitre Vascular, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of 2.72.

Company Profile

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Exchange Ticker
NMS (United States) LMAT
FRA (Germany) LHU.F
Trades
Dividend Yield
0.98%
5y avg 0.87%
Annual Dividends
0.90USD
Next Ex. Div Date
May 21, 2026
Payout Ratio
30.93%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
2027
0.57 USD
June 3, 2027 (estimated) 0.2845
March 4, 2027 (estimated) 0.2848
2026
0.96 USD
Dec. 3, 2026 (estimated) 0.2294
Sept. 3, 2026 (estimated) 0.2294
June 4, 2026 0.2500
March 26, 2026 0.2500
2025
0.80 USD
Dec. 4, 2025 0.2000
Sept. 4, 2025 0.2000
May 29, 2025 0.2000
March 27, 2025 0.2000
2024
0.64 USD
Dec. 5, 2024 0.1600
Aug. 29, 2024 0.1600
May 30, 2024 0.1600
March 28, 2024 0.1600
2023
0.56 USD
Nov. 30, 2023 0.1400
Aug. 31, 2023 0.1400
June 1, 2023 0.1400
March 23, 2023 0.1400
2022
0.50 USD
Dec. 1, 2022 0.1250
Sept. 8, 2022 0.1250
June 2, 2022 0.1250
March 24, 2022 0.1250
2021
0.44 USD
Dec. 2, 2021 0.1100
Sept. 9, 2021 0.1100
June 3, 2021 0.1100
March 25, 2021 0.1100
2020
0.38 USD
Dec. 3, 2020 0.0950
Sept. 10, 2020 0.0950
June 4, 2020 0.0950
March 19, 2020 0.0950
2019
0.34 USD
Dec. 5, 2019 0.0850
Sept. 5, 2019 0.0850
June 6, 2019 0.0850
April 5, 2019 0.0850
2018
0.28 USD
Dec. 6, 2018 0.0700
Sept. 6, 2018 0.0700
June 7, 2018 0.0700
April 5, 2018 0.0700
2017
0.22 USD
Dec. 7, 2017 0.0550
Sept. 7, 2017 0.0550
June 8, 2017 0.0550
April 6, 2017 0.0550
2016
0.18 USD
Dec. 5, 2016 0.0450
Sept. 6, 2016 0.0450
June 8, 2016 0.0450
April 4, 2016 0.0450
2015
0.16 USD
Dec. 4, 2015 0.0400
Sept. 3, 2015 0.0400
June 5, 2015 0.0400
April 3, 2015 0.0400
2014
0.14 USD
Dec. 4, 2014 0.0350
Sept. 4, 2014 0.0350
June 5, 2014 0.0350
April 3, 2014 0.0350
2013
0.12 USD
Dec. 4, 2013 0.0300
Sept. 4, 2013 0.0300
June 5, 2013 0.0300
April 3, 2013 0.0300
2012
0.10 USD
Dec. 4, 2012 0.0250
Sept. 4, 2012 0.0250
June 4, 2012 0.0250
April 3, 2012 0.0250
2011
0.08 USD
Dec. 6, 2011 0.0200
Sept. 6, 2011 0.0200
June 6, 2011 0.0200
April 5, 2011 0.0200
Upcoming Dividends
Name Payment Date Status Amount
LeMaitre Vascular, Inc. Jun 04, 2026 0.25 USD
LeMaitre Vascular, Inc. Mar 26, 2026 0.25 USD
LeMaitre Vascular, Inc. Dec 04, 2025 0.2 USD
LeMaitre Vascular, Inc. Sep 04, 2025 0.2 USD
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion